- Home
- DAY vs ROIV Comparison
DAY vs ROIV Comparison
Compare DAY & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAY
- ROIV
- Stock Information
- Founded
- DAY 1992
- ROIV 2014
- Country
- DAY United States
- ROIV United Kingdom
- Employees
- DAY N/A
- ROIV N/A
- Industry
- DAY
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- DAY
- ROIV Health Care
- Exchange
- DAY NYSE
- ROIV Nasdaq
- Market Cap
- DAY 8.9B
- ROIV 7.8B
- IPO Year
- DAY 2018
- ROIV N/A
- Fundamental
- Price
- DAY $60.01
- ROIV $11.55
- Analyst Decision
- DAY Buy
- ROIV Buy
- Analyst Count
- DAY 13
- ROIV 3
- Target Price
- DAY $72.23
- ROIV $15.25
- AVG Volume (30 Days)
- DAY 1.4M
- ROIV 6.4M
- Earning Date
- DAY 08-06-2025
- ROIV 08-07-2025
- Dividend Yield
- DAY N/A
- ROIV N/A
- EPS Growth
- DAY N/A
- ROIV N/A
- EPS
- DAY 0.16
- ROIV N/A
- Revenue
- DAY $1,810,300,000.00
- ROIV $29,053,000.00
- Revenue This Year
- DAY $11.08
- ROIV $3.28
- Revenue Next Year
- DAY $10.69
- ROIV $156.84
- P/E Ratio
- DAY $372.79
- ROIV N/A
- Revenue Growth
- DAY 14.97
- ROIV N/A
- 52 Week Low
- DAY $48.01
- ROIV $8.73
- 52 Week High
- DAY $82.69
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- DAY 59.69
- ROIV 55.27
- Support Level
- DAY $57.09
- ROIV $11.31
- Resistance Level
- DAY $58.94
- ROIV $11.64
- Average True Range (ATR)
- DAY 1.47
- ROIV 0.29
- MACD
- DAY 0.45
- ROIV 0.00
- Stochastic Oscillator
- DAY 99.59
- ROIV 78.60
About DAY DAYFORCE INC
Dayforce is a global technology company providing cloud-based human capital management solutions for large businesses looking to manage their payroll, tax, benefits, and talent intelligence. The company primarily services customers in the US with its flagship Dayforce platform but also services customers in select European countries as well as Australia and New Zealand. Dayforce services the Canadian HCM market with its Powerpay platform that specifically targets customers with less than 100 employees. As of fiscal 2024, the Dayforce platform accounted for almost 80% of companywide revenue and had 6,876 clients representing approximately 7.62 million employees.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.